Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1619931-27-9
2. Gb002
3. (s)-n-(3-(1-((6-(3,4-dimethoxyphenyl)pyrazin-2-yl)amino)ethyl)phenyl)-5-methylnicotinamide
4. Pk-10571
5. Seralutinib [usan]
6. Gb-002
7. 3p63zte3oy
8. N-[3-[(1s)-1-[[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino]ethyl]phenyl]-5-methylpyridine-3-carboxamide
9. 3-pyridinecarboxamide, N-(3-((1s)-1-((6-(3,4-dimethoxyphenyl)-2-pyrazinyl)amino)ethyl)phenyl)-5-methyl-
10. Seralutinib [inn]
11. Unii-3p63zte3oy
12. Seralutinib [who-dd]
13. Chembl4650333
14. Schembl17324860
15. Gtpl10618
16. Ex-a5138
17. Who 11243
18. At11371
19. Pk10571
20. Structure 2a [wo2014110200a1]
21. Hy-109190
22. Cs-0116463
23. N-(3-((1s)-1-((6-(3,4-dimethoxyphenyl)-2-pyrazinyl)amino)ethyl)phenyl)-5-methyl-3-pyridinecarboxamide
Molecular Weight | 469.5 g/mol |
---|---|
Molecular Formula | C27H27N5O3 |
XLogP3 | 3.7 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 8 |
Exact Mass | 469.21138974 g/mol |
Monoisotopic Mass | 469.21138974 g/mol |
Topological Polar Surface Area | 98.3 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 667 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Seralutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Seralutinib, including repackagers and relabelers. The FDA regulates Seralutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Seralutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Seralutinib supplier is an individual or a company that provides Seralutinib active pharmaceutical ingredient (API) or Seralutinib finished formulations upon request. The Seralutinib suppliers may include Seralutinib API manufacturers, exporters, distributors and traders.
Seralutinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Seralutinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Seralutinib GMP manufacturer or Seralutinib GMP API supplier for your needs.
A Seralutinib CoA (Certificate of Analysis) is a formal document that attests to Seralutinib's compliance with Seralutinib specifications and serves as a tool for batch-level quality control.
Seralutinib CoA mostly includes findings from lab analyses of a specific batch. For each Seralutinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Seralutinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Seralutinib EP), Seralutinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Seralutinib USP).
LOOKING FOR A SUPPLIER?